Manufacturing roundup: Quality issues at Sun Pharma plant in India; Forge secures gene therapy manufacturing contract
The FDA has revealed further issues at a Sun Pharma manufacturing facility in India.
Last month, Sun Pharma announced it was pausing production at one of its plants in Mohali, India, after facing scrutiny by US regulators over necessary corrective work. US regulators ultimately conveyed to the company that it needs to take corrective actions at the manufacturing facility before it can ship any products to the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.